NRAS and hepatocellular carcinoma: Eight of 20 (40.0 %) patients with HCC had a prior anti-VEGF treatment and 14 (70.0 %) of them were Child-Pugh A. Ten of 19 (52.6 %) melanoma patients had NRAS mutation, one (5.3 %) was wild type, and eight (42.1 %) were unknown.